B. Riley Comments on MacroGenics' Q2 Earnings (NASDAQ:MGNX)

MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Stock analysts at B. Riley issued their Q2 2025 earnings estimates for MacroGenics in a research report issued to clients and investors on Monday, May 19th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings of ($0.49) per share for the quarter. B. Riley has a "Neutral" rating and a $3.00 price objective on the stock. The consensus estimate for MacroGenics' current full-year earnings is ($1.06) per share. B. Riley also issued estimates for MacroGenics' Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at $0.72 EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.59) EPS and FY2029 earnings at ($0.86) EPS.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The firm had revenue of $13.19 million during the quarter, compared to the consensus estimate of $9.59 million.

A number of other analysts have also recently weighed in on the stock. Stifel Nicolaus lowered their price target on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating on the stock in a report on Wednesday, May 14th. Barclays reiterated an "overweight" rating and issued a $3.00 target price (down from $8.00) on shares of MacroGenics in a research note on Wednesday, May 14th. Wall Street Zen lowered shares of MacroGenics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reduced their price target on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, MacroGenics currently has a consensus rating of "Hold" and an average price target of $5.71.

MacroGenics Stock Up 1.0%

MGNX stock traded up $0.02 during trading on Thursday, hitting $1.53. The company had a trading volume of 83,364 shares, compared to its average volume of 796,368. MacroGenics has a 52-week low of $0.99 and a 52-week high of $5.77. The company has a 50 day simple moving average of $1.48 and a 200-day simple moving average of $2.49. The firm has a market capitalization of $96.21 million, a P/E ratio of -0.97 and a beta of 2.20.

Institutional Investors Weigh In On MacroGenics

Several hedge funds have recently modified their holdings of the business. State of Wyoming bought a new position in MacroGenics in the first quarter worth $28,000. Lazard Asset Management LLC bought a new position in MacroGenics in the fourth quarter worth $32,000. American Century Companies Inc. bought a new position in MacroGenics in the fourth quarter worth $38,000. Jump Financial LLC bought a new position in MacroGenics in the fourth quarter worth $44,000. Finally, Deutsche Bank AG lifted its position in MacroGenics by 3,803.2% in the first quarter. Deutsche Bank AG now owns 51,093 shares of the biopharmaceutical company's stock worth $65,000 after purchasing an additional 49,784 shares during the period. 96.89% of the stock is owned by institutional investors.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.